The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment
Open accessAbstract
The amyloidoses are a group of systemic diseases characterized by organ deposition of misfolded protein fragments of diverse origins. The natural history of the disease, involvement of other organs, and treatment options vary significantly based on the protein of origin. In AL amyloidosis, amyloid protein is derived from immunoglobulin light chains, and most often involves the kidneys and the heart. ATTR amyloidosis is categorized as mutant or wild-type depending on the genetic sequence of the transthyretin (TTR) protein produced by the liver. Wild-type ATTR amyloidosis mainly involves the heart, although the reported occurrence of bilateral carpal tunnel syndrome, spinal stenosis and biceps tendon rupture in these patients speaks to more generalized protein deposition. Mutant TTR is marked by cardiac and/or peripheral nervous system involvement. Cardiac involvement is associated with symptoms of heart failure, and dictates the clinical course of the disease. Cardiac amyloidosis can be diagnosed noninvasively by echocardiography, cardiac MRI, or nuclear scintigraphy. Endomyocardial biopsy may be needed in the case of equivocal imaging findings or discordant data. Treatment is aimed at relieving congestive symptoms and targeting the underlying amyloidogenic process. This includes anti-plasma cell therapy in AL amyloidosis, and stabilization of the TTR tetramer or inhibition of TTR protein production in ATTR amyloidosis. Cardiac transplantation can be considered in highly selected patients in tandem with therapy aimed at suppressing the amyloidogenic process, and appears associated with durable long term survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Gillmore, J. D., Maurer, M. S., Falk, R. H., Merlini, G., Damy, T., Dispenzieri, A., Wechalekar, A. D., Berk, J. L., Quarta, C. C., Grogan, M., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.021612 · Cited by 2,081
Self-citationMolecular Mechanisms of Amyloidosis
Merlini, G., & Bellotti, V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023144 · Cited by 1,920
Mehra, M. R., Canter, C. E., Hannan, M. M., Semigran, M. J., Uber, P. A., Baran, D. A., Danziger-Isakov, L., Kirklin, J. K., Kirk, R., Kushwaha, S. S., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.10.023 · Cited by 1,431
Gertz, M. A., Comenzo, R., Falk, R. H., Fermand, J. P., Hazenberg, B. P., Hawkins, P. N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., et al. (2005) · American Journal of Hematology · doi:10.1002/ajh.20381 · Cited by 1,428
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction
González-López, E., Gallego-Delgado, M., Guzzo-Merello, G., de Haro-del Moral, F. J., Cobo-Marcos, M., Robles, C., Bornstein, B., Salas, C., Lara-Pezzi, E., Alonso-Pulpon, L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv338 · Cited by 1,174
Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Colby, C., Laumann, K., Zeldenrust, S. R., Leung, N., Dingli, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.5724 · Cited by 1,137
Review: History of the Amyloid Fibril
Sipe, J. D., & Cohen, A. S. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4221 · Cited by 1,054
Dispenzieri, A., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Burritt, M. F., Therneau, T. M., Greipp, P. R., Witzig, T. E., Lust, J. A., Rajkumar, S. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.029 · Cited by 985
Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
Maceira, A. M., Joshi, J., Prasad, S. K., Moon, J. C., Perugini, E., Harding, I., Sheppard, M. N., Poole-Wilson, P. A., Hawkins, P. N., & Pennell, D. J. (2005) · Circulation · doi:10.1161/01.cir.0000152819.97857.9d · Cited by 982
Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types
Rapezzi, C., Merlini, G., Quarta, C. C., Riva, L., Longhi, S., Leone, O., Salvi, F., Ciliberti, P., Pastorelli, F., Biagini, E., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.843334 · Cited by 774
Cited by
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R. H., Ferrari, V. A., Fontana, M., Gheysens, O., Gillmore, J. D., Glaudemans, A. W. J. M., et al. (2019) · Journal of Nuclear Cardiology · doi:10.1007/s12350-019-01760-6 · Cited by 484
Self-citationSystemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review
Gertz, M. A., & Dispenzieri, A. (2020) · JAMA · doi:10.1001/jama.2020.5493 · Cited by 366
Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice
Witteles, R. M., Bokhari, S., Damy, T., Elliott, P. M., Falk, R. H., Fine, N. M., Gospodinova, M., Obici, L., Rapezzi, C., & Garcia-Pavia, P. (2019) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.04.010 · Cited by 351
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R. H., Ferrari, V. A., Fontana, M., Gheysens, O., Gillmore, J. D., Glaudemans, A. W. J. M., et al. (2021) · Circulation: Cardiovascular Imaging · doi:10.1161/hci.0000000000000029 · Cited by 275
Self-citationThe Dual-Tree Complex Wavelet Transform: A New Efficient Tool For Image Restoration And Enhancement
Kingsbury, N. (1998) · doi:10.5281/zenodo.36900 · Cited by 272
Metadata
- Authors
- Siddiqi, O. K., & Ruberg, F. L.
- Venue
- Trends in Cardiovascular Medicine
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 28
- Issue
- 1
- Pages
- 10-21
- ISSN
- 1050-1738 (ISSN-L)
- OpenAlex
- W2735021378
- Cited by
- 333
- References
- 70
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. https://app.cochat.ai/papers/10.1016/j.tcm.2017.07.004
- The paper
- Siddiqi, O. K., & Ruberg, F. L. (2018). Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends in Cardiovascular Medicine. https://doi.org/10.1016/j.tcm.2017.07.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.